Nexentis Technologies

Nexentis Technologies Inc. (NASDAQ: NXTS) is an AI-driven biotechnology company specializing in mitochondrial biology and computational drug discovery. Through its wholly owned subsidiary, MitoCareX Bio, the company leverages its proprietary MITOLINE™ platform to target the mitochondrial SLC25 carrier family, a historically undrugged class of transport proteins. The company's research focuses on developing first-in-class small-molecule therapeutics for precision oncology, specifically targeting lung and pancreatic cancers, as well as inflammatory metabolic diseases. Nexentis aims to accelerate the drug discovery process by integrating advanced in silico modeling with experimental validation. In addition to its biotech core, the company maintains strategic investments in renewable energy and post-harvest food treatment technologies.